Evidence map›Paper›PMID 32044844›Full record

ArticleAIDS (London, England)2020

Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum.

Noah A Haber, Catherine R Lesko, Matthew P Fox, Kimberly A Powers, Guy Harling, Jessie K Edwards, Joshua A Salomon, Sheri A Lippman, Jacob Bor, Angela Y Chang and 2 more

Open access · hybridAbstract read
In one paragraph

Article in AIDS (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A two-day workshop reviewing Canadian provincial and national HIV care cascade indicators, reporting, challenges, and recommendations.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Noah A HaberCarolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Catherine R LeskoDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
Matthew P FoxDepartment of Global Health.
Kimberly A PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Guy HarlingInstitute for Global Health, University College London, London, UK.
Jessie K EdwardsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Joshua A SalomonCenter for Health Policy and Center for Primary Care and Outcomes Research, Department of Medicine, School of Medicine, Stanford University, Stanford.
Sheri A LippmanMRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jacob BorDepartment of Global Health.
Angela Y ChangDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Andrew AnglemyerNaval Postgraduate School, Operations Research Department, Monterey, California, USA.
Audrey PettiforCarolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
University of North Carolina at Chapel Hill · USAgincourt Health and Socio-Demographic Surveillance System · ZAUniversity of the Witwatersrand · ZAHarvard Global Health Institute · USJohns Hopkins University · USStanford University · USUniversity of California, San Francisco · USUniversity of Otago · NZ

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
POPULATION STUDIEST32HD007168 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELIZABETH A FRANKENBERG · 1985 to 2026
$13.8M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Activating Treatment as Prevention through Community Mobilization in South AfricaR01MH103198 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIPPMAN, SHERI ANN, PETTIFOR, AUDREY · 2014 to 2018
$3.1M
Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
Evaluating UTT with a National HIV Cohort to Optimize South Africa's HIV Response (ENCORE)R01AI152149 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI BOR, JACOB, ONOYA, DORINA · 2020 to 2024
$1.8M
Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuumK01AA028193 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI LESKO, CATHERINE · 2019 to 2023
$900k
Economic, health, and behavioral dimensions of HIV treatment scale-upK01MH105320 · NIMH · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOR, JACOB · 2015 to 2018
$613k
Comparative effectiveness of tailored HIV treatment plans and mortalityK01AI125087 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EDWARDS, JESSIE · 2017 to 2021
$586k
NIAAA NIH HHS K01 AA028193NIAID NIH HHS K01 AI125087NICHD NIH HHS P2C HD050924NICHD NIH HHS R01 HD084233NICHD NIH HHS T32 HD007168NIMH NIH HHS K01 MH105320NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH103198
6 · The paper itself

Abstract

objectivesThe Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 and other cross-sectional metrics can lead to potentially counterintuitive conclusions when used to evaluate health systems' performance. This study demonstrates how time and population dynamics impact UNAIDS 90-90-90 metrics in comparison with a longitudinal analogue.

designA simplified simulation representing a hypothetical population was used to estimate and compare inference from UNAIDS 90-90-90 metrics and longitudinal metrics based on Kaplan-Meier-estimated 2-year probability of transition between stages.

methodsWe simulated a large cohort over 15 years. Everyone started out at risk for HIV, and then transitioned through the HIV care continuum based on fixed daily probabilities of acquiring HIV, learning status, entering care, initiating antiretroviral therapy (ART), and becoming virally suppressed, or dying. We varied the probability of ART initiation over three five-year periods (low, high, and low). We repeated the simulation with an increased probability of death.

resultsThe cross-sectional probability of being on ART among persons who were diagnosed responded relatively slowly to changes in the rate of ART initiation. Increases in ART initiation rates caused apparent declines in the cross-sectional probability of being virally suppressed among persons who had initiated ART, despite no changes in the rate of viral suppression. In some cases, higher mortality resulted in the cross-sectional metrics implying improved healthcare system performance. The longitudinal continuum was robust to these issues.

conclusionThe UNAIDS 90-90-90 care continuum may lead to incorrect inference when used to evaluate health systems performance. We recommend that evaluation of HIV care delivery include longitudinal care continuum metrics wherever possible.

Indexed as

Continuity of Patient CareAnti-HIV AgentsBenchmarkingCross-Sectional StudiesHIV InfectionsHumansAnti-HIV Agents

Identifiers

PMID32044844
PMCPMC7253182
OpenAlexW3007955478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.